Most Enhertu side effects appear within the first few weeks of treatment and follow a pattern that varies by type: nausea and vomiting tend to peak early and can recur with each infusion cycle, fatigue often sets in within the first month and persists at a low hum throughout treatment, and the rarest but most serious complication, lung inflammation, can emerge months into therapy and take weeks to months to resolve. The timeline is not one-size-fits-all, and the severity of each side effect shapes how long it lingers. Understanding these patterns helps you know what to watch for, when to raise concerns with your oncologist, and what relief is realistic.
Nausea and Vomiting Are Among the Earliest and Most Common Effects
Nausea is the side effect most patients notice first. It can start within hours of an Enhertu infusion and shows up in a large majority of people receiving the drug. What makes it tricky is the timing: unlike some chemotherapy agents where nausea peaks acutely and then fades, Enhertu belongs to a class of treatments (antibody-drug conjugates) where nausea and vomiting can persist well past the first day or two, stretching into what oncologists call the “long-delayed” period. This means you might feel queasy not just on infusion day but for several days afterward, and sometimes into the second week of a three-week cycle.
The duration of nausea tends to shorten as your medical team fine-tunes your anti-nausea regimen. Standard antiemetic drugs are given before each infusion, but emerging evidence suggests that certain combination antiemetics with longer-acting properties may do a better job controlling the late-onset nausea that antibody-drug conjugates like Enhertu produce. A narrative review noted that these drugs are associated with high rates of both acute and late-onset nausea and vomiting that can last for an extended duration, and highlighted the fixed-combination antiemetic NEPA as a promising approach for longer control.1PubMed Central. Nausea and vomiting in an evolving anticancer treatment landscape: long-delayed and emetogenic antibody-drug conjugates If your nausea is lasting more than a few days after each infusion or worsening with successive cycles, that is worth bringing up, because adjusting the anti-nausea strategy can make a real difference in day-to-day quality of life.
Vomiting is less common than nausea but follows a similar timeline. Most patients who experience vomiting find it manageable with medication, and severe vomiting (the kind that leads to dehydration or hospitalization) is uncommon. Diarrhea and decreased appetite round out the gastrointestinal picture and can persist at a low level between cycles, though for most people they do not worsen dramatically over time.
Fatigue Tends to Settle In Early and Stick Around
Fatigue is one of the most persistent side effects of Enhertu. Data from the DESTINY-Breast clinical trials showed that fatigue or a general sense of weakness affected roughly a third to nearly half of patients at any grade, with severe fatigue occurring in a smaller subset. The median time to first feeling fatigue was about 22 days from the start of treatment, and its frequency stayed fairly steady from one treatment cycle to the next rather than getting progressively worse.2PubMed Central. Safety profile of trastuzumab deruxtecan in advanced breast cancer: Expert opinion on adverse event management
That steady-state pattern is both reassuring and frustrating. Reassuring because you are unlikely to feel increasingly wiped out with every cycle. Frustrating because the fatigue does not disappear between infusions the way acute nausea might. Many patients describe it as a persistent low-grade tiredness that makes daily activities harder without being completely disabling. The clinical data from DESTINY-Breast03 reported no cases of life-threatening fatigue, which means for almost everyone it stays in a range that can be managed with pacing, sleep hygiene, and activity adjustments.2PubMed Central. Safety profile of trastuzumab deruxtecan in advanced breast cancer: Expert opinion on adverse event management
One thing to keep in mind: fatigue from Enhertu can overlap with fatigue from the cancer itself, from previous lines of treatment, or from emotional exhaustion. It can be hard to tease apart what is causing what, and your oncology team will usually focus on treatable contributors like anemia, thyroid dysfunction, or poor sleep rather than trying to assign blame to one single cause.
Interstitial Lung Disease Is the Most Serious Risk
The side effect that gets the most attention, and rightly so, is interstitial lung disease, often called ILD or pneumonitis. This is an inflammatory reaction in the lungs that can cause cough, shortness of breath, and in severe cases, significant breathing difficulty. It is far less common than nausea or fatigue, but its potential severity is what puts it at the top of every Enhertu risk discussion.
ILD does not announce itself on day one. It typically shows up months into treatment. One systematic review of investigator-reported cases found a median onset of about 193 days from the start of Enhertu, with a wide range from roughly six weeks to over a year and a half.3PubMed Central. Trastuzumab Deruxtecan-Induced Interstitial Lung Disease/Pneumonitis in ERBB2-Positive Advanced Solid Malignancies: A Systematic Review A separate real-world retrospective study found a shorter median onset of 81 days, with a range from as early as one day to about nine months.4The Journal of Hematology Oncology Pharmacy. Incidence and Outcomes of Pneumonitis/Interstitial Lung Disease in Patients Receiving Trastuzumab Deruxtecan The variation between studies reflects differences in how closely patients were monitored and how mild cases were captured. The bottom line is that ILD can appear anywhere from the first couple of months to well past the one-year mark, which is why regular lung monitoring continues throughout the entire course of treatment.
How Long Lung Inflammation Takes to Resolve
When ILD is caught early and at a low grade, recovery is the expected outcome for most patients, but it takes time. The systematic review cited above reported a median recovery time of about 34 days from the onset of symptoms, though some patients took nearly six months to fully recover.3PubMed Central. Trastuzumab Deruxtecan-Induced Interstitial Lung Disease/Pneumonitis in ERBB2-Positive Advanced Solid Malignancies: A Systematic Review The real-world cohort study reported a somewhat longer median resolution time of 44 days, with some cases stretching past eight months.4The Journal of Hematology Oncology Pharmacy. Incidence and Outcomes of Pneumonitis/Interstitial Lung Disease in Patients Receiving Trastuzumab Deruxtecan A Japanese imaging study found an even longer median of roughly 84 days to recovery but also reported that about three-quarters of patients did eventually recover, including some who were left with mild residual lung changes that did not cause ongoing symptoms.5PubMed Central. Clinical and imaging features of interstitial lung disease in cancer patients treated with trastuzumab deruxtecan
The spread in these numbers is not a sign that the science is unreliable. It reflects the reality that ILD severity varies enormously. A mild case caught on a routine CT scan when you feel fine will resolve much faster than a case that has already progressed to moderate breathing difficulty. Grade matters, and the earlier it is detected, the shorter the recovery window tends to be.
Enhertu is paused or permanently discontinued when ILD is diagnosed, depending on the grade. For mild cases, your oncologist may hold treatment, start steroids, and monitor you closely with the possibility of restarting Enhertu once the inflammation clears. For moderate or severe cases, Enhertu is typically stopped for good, and steroid therapy becomes the primary treatment for the lung inflammation itself.
Steroid Treatment and ILD Management
Corticosteroids are the main treatment for Enhertu-related ILD, and how quickly they are started can affect how the lung inflammation plays out. Current guidelines recommend starting steroids promptly for moderate-grade ILD and suggest that even mild cases may warrant steroid treatment, particularly if imaging shows extensive lung involvement or if the patient has risk factors that could lead the inflammation to worsen.6ESMO Open. Management of trastuzumab deruxtecan (T-DXd) interstitial lung disease and other adverse events in breast cancer The reasoning is straightforward: early steroid treatment may help prevent mild ILD from escalating to a higher grade, which is where the real danger lies.
Steroid courses for ILD are not brief. A typical regimen involves a high initial dose followed by a slow taper over weeks. Some patients are on steroids for two months or more, and the steroids themselves bring side effects: sleep disruption, mood changes, elevated blood sugar, increased appetite, and a general sense of being “wired.” These steroid-related effects add another layer to the recovery experience that patients should be prepared for.
If you are on Enhertu and develop a new cough, increasing shortness of breath, or chest discomfort, report it immediately. One of the challenges is that these symptoms are common in people with advanced cancer for many reasons, from lung metastases to deconditioning. Your oncology team will use imaging and your clinical picture to distinguish ILD from other causes. The vigilance is warranted because early intervention genuinely changes outcomes.
Who Is at Higher Risk for Lung Problems
Not everyone on Enhertu faces the same risk of developing ILD. A retrospective cohort study of patients with metastatic breast cancer identified several factors associated with higher pneumonitis risk. Having pre-existing lung abnormalities visible on imaging (called interstitial lung abnormalities, or ILAs) was the strongest predictor, increasing the risk dramatically. Shortness of breath before starting treatment, a greater number of prior treatment lines, triple-negative breast cancer subtype, and lower HER2 expression levels were also associated with increased risk.7PubMed Central. Incidence and risk factors for pneumonitis due to trastuzumab Deruxtecan in metastatic breast cancer: a retrospective cohort study
The finding about pre-existing lung abnormalities is particularly useful because it is something that can be screened for before starting treatment. If your baseline CT scan shows ILAs, your oncologist may increase monitoring frequency or discuss whether the benefit-to-risk balance still favors Enhertu over alternative options. It does not automatically disqualify you from receiving the drug, but it changes the conversation about how closely you need to be watched.
The link between more prior treatments and higher ILD risk may partly reflect cumulative lung exposure from prior therapies, or it may simply mean that patients who have been through more lines of treatment tend to be frailer and have less lung reserve. Either way, it is a factor your medical team will weigh.
Why Enhertu Causes Off-Target Effects
The side effect profile of Enhertu is tied to how the drug works. Enhertu is an antibody-drug conjugate: an antibody that targets HER2 on cancer cells, linked to a powerful chemotherapy payload. When the antibody binds a cancer cell, the whole package gets pulled inside the cell, the linker is cleaved, and the chemotherapy payload is released to kill it. The wrinkle is that Enhertu uses a cleavable linker, meaning the payload can also be released outside the target cell by enzymes in the surrounding tissue. This “bystander effect” is actually part of what makes Enhertu effective, because it can kill nearby cancer cells that do not express much HER2 on their own.
But that same mechanism is also a potential source of off-target toxicity. Research on Enhertu’s activity in melanoma models found that the drug’s effectiveness in living tissue appeared to be largely driven by payload release in the tumor microenvironment rather than by direct HER2 targeting alone, and the investigators noted that this highlights how cleavable-linker antibody-drug conjugates carry both a therapeutic opportunity and a risk of off-target damage.8Clinical Cancer Research. Abstract A011: Trastuzumab deruxtecan kills skin and uveal melanoma in vivo by HER2-independent payload release Healthy tissues that happen to have the right enzyme activity can get caught in the crossfire, which helps explain why the lungs, the gut lining, and the bone marrow are all affected to varying degrees.
This is a key distinction from some older HER2-targeted therapies. An in vitro comparison between Enhertu and the older antibody-drug conjugate Kadcyla (ado-trastuzumab emtansine) showed that Kadcyla, which uses a non-cleavable linker and a membrane-impermeable payload, had a much more limited bystander effect.9Cancer Research. Abstract 2891: In vitro comparison of Kadcyla and Enhertu in breast cancer with varying HER2 expression: proliferation, internalization, bystander effects and toxicity The tradeoff is that Kadcyla is less effective in tumors with lower or heterogeneous HER2 expression. Enhertu’s broader reach is both its clinical advantage and the reason its side effect profile is wider.
Hair Loss, Blood Count Changes, and Other Effects
Hair thinning or loss (alopecia) is common with Enhertu, reported in roughly half of patients across clinical trials. It typically begins within the first couple of cycles and progresses over several months. Unlike some forms of chemotherapy-induced hair loss that happen all at once, Enhertu-related hair loss is often more gradual, with many patients experiencing thinning rather than complete baldness. Hair generally begins to regrow after treatment is stopped, though this can take several months.
Low blood counts are another expected effect. Enhertu’s chemotherapy payload, a topoisomerase I inhibitor called deruxtecan, suppresses bone marrow activity, which can lead to drops in white blood cells (raising infection risk), red blood cells (contributing to fatigue and shortness of breath), and platelets (increasing bruising and bleeding risk). These changes are monitored with routine blood tests before each infusion cycle. The drops tend to hit a low point (called a nadir) about one to two weeks after an infusion and recover before the next cycle. If counts drop too low, your oncologist may delay treatment or adjust the dose.
Decreased appetite and weight loss can accumulate over the course of treatment, driven by nausea, taste changes, and the general metabolic effects of the drug. Nutritional support from a dietitian experienced in oncology can be helpful in staying ahead of this, particularly if you are already underweight or have struggled with eating during prior treatments.
How Dose Reductions Affect Side Effect Duration
One of the most practical tools for managing Enhertu side effects is dose reduction. If you are experiencing persistent nausea, fatigue, or blood count problems that are not well controlled by supportive medications, your oncologist may lower the dose from the standard 5.4 mg/kg to 4.4 mg/kg, or further to 3.2 mg/kg. These reductions can meaningfully shorten the duration and severity of side effects between cycles while preserving the drug’s anticancer activity. Clinical trial data suggest that patients who undergo dose reductions can continue to benefit from treatment, so a lower dose is not a failure; it is a calibration.
Dose reductions do not eliminate side effects entirely, but they can shrink the window of feeling unwell after each infusion. For nausea in particular, patients who had their dose reduced often report that the number of “bad days” per cycle drops from several to one or two. Fatigue may become more manageable as well, though it rarely disappears completely while you remain on treatment.
What Happens After You Stop Enhertu
The timeline for side effects fading after discontinuation depends on which effect you are tracking. Nausea and vomiting typically resolve within a week or two of the last infusion, since they are tied to each drug cycle. Fatigue can linger longer, sometimes for weeks to a couple of months, as your body recovers from the cumulative effects of treatment. Blood counts generally bounce back within a few weeks. Hair regrowth begins within one to three months for most people, though the texture and color of regrown hair can differ from what you had before treatment.
ILD, if it developed during treatment, follows its own recovery arc as discussed earlier and is managed with steroids independently of whether Enhertu continues. Some patients who developed mild ILD and had it resolve successfully have been cautiously re-challenged with Enhertu at a lower dose, though this is a case-by-case decision that involves weighing the cancer treatment options you have left against the risk of recurrence.
Eye-Related Side Effects
Some patients on Enhertu or similar antibody-drug conjugates report eye-related side effects, including dry eyes, blurred vision, or changes in the surface of the cornea. These are generally mild and more commonly associated with certain other ADCs that carry different payloads, but they have been noted in the Enhertu literature as well. If you notice vision changes while on treatment, mention them to your oncology team. An ophthalmology referral can help determine whether the changes are drug-related and whether lubricating eye drops or other simple measures are sufficient.
The mechanism behind ocular side effects in ADCs is thought to be related to the active drug component reaching the corneal epithelium, which turns over rapidly and may be vulnerable to the same cytotoxic effects that target cancer cells. For Enhertu specifically, severe eye toxicity is rare, and most reported cases resolve with conservative management or after treatment is adjusted. Still, it is an effect that often goes unmentioned in initial counseling, and patients who experience it may be alarmed if they were not warned it was a possibility.